


# **Symbiotic Relationship between Human and Bifidobacteria**


**Kenji YAMAMOTO**

**Graduate School of Biostudies, Kyoto University**



*Bifidobacterium longum*

# Classification of Major Lactic Acid Bacteria



# History of Bifidobacteria

## 1899 Tissier

Tissier found and isolated a new bacterium from infant's feces, and named the bacteria as '*Bacillus bifidus communis*'.  
This is the finding of bifidobacteria.

## 1924 Orla-Jensen

Orla-Jensen proposed to establish new genus '*Bifidobacterium*', but the proposal was not accepted.

## 1933~1934 Weiss and Rettger

They regarded bifidobacteria as a species of Lactobacilli and classified into genus '*Lactobacillus*'.

## 1958~ Ochi and Mitsuoka et al, Rogosa et al, Sharpe, Reuter, Werner

Bifidobacteria were excluded from genus '*Lactobacillus*' and genus '*Bifidobacterium*' was newly established.

# Various Bifidobacteria were Isolated from Various Sources

## Human Origin

<i>B. adolescentis</i>	(adult faeces)
<i>B. angulatum</i>	(adult faeces)
<i>B. bifidum</i>	(child and adult faeces, vagina)
<i>B. breve</i>	(child faeces, vagina)
<i>B. catenulatum</i>	(child and adult faeces, vagina)
<i>B. denticolens</i>	(buccal cavity, adult faeces)
<i>B. dentium</i>	(buccal cavity, adult faeces)
<i>B. gallicum</i>	(adult faeces)
<i>B. infantis</i>	(child faeces, vagina)
<i>B. inopinatum</i>	(buccal cavity)
<i>B. longum</i>	(child and adult faeces, vagina)
<i>B. pseudocatenulatum</i>	(child faeces)

## Animal Origin

<i>B. animalis</i>	(rat, chicken, rabbit and calf faeces)
<i>B. asteroides</i>	(bees)
<i>B. boum</i>	(rumen, piglet faeces)
<i>B. choerium</i>	(piglet faeces)
<i>B. coryneforme</i>	(bees)
<i>B. cuniculi</i>	(rabbit faeces)
<i>B. gallinarum</i>	(chicken faeces)
<i>B. indicum</i>	(bees)
<i>B. magnum</i>	(rabbit faeces)
<i>B. merycicum</i>	(rumen)
<i>B. pseudolongum pseudolongum</i>	(piglet, chicken, calf and rat faeces, rumen)
<i>B. pseudolongum globosum</i>	(piglet, chicken, calf and rat faeces, rumen)
<i>B. pullorum</i>	(chicken faeces)
<i>B. ruminantium</i>	(rumen)
<i>B. saeculare</i>	(rabbit faeces)
<i>B. suis</i>	(piglet faeces)
<i>B. thermophilum</i>	(piglet, chicken and calf faeces, rumen)

## Environmental and Food Origins

<i>B. lactis</i>	(fermented milk)
<i>B. minimum</i>	(sewage)
<i>B. subtile</i>	(sewage)
<i>B. thermacidophilum</i>	(anaerobic digester)

Most of Bifidobacteria are found in human and animal sources

# Bifidobacteria Decrease with Aging of Human

Infant  
(breastfed)



Adolescent



Elderly



Ratio in flora

**90~%**

**~6%**

Major species


*B. infantis*  
*B. breve*  
*B. longum*



*B. adolescentis*  
*B. longum*  
*B. catenulatum*

Ratio of Bifidobacteria in human flora is decreased  
and their species are changed with aging

# Bifidobacteria are Approved as Probiotics



## The number of LAB listed in ‘CIAA EU Nutrition and Health Claims Regulation’

Lactobacilli	Number
<i>L. acidophilus</i>	15
<i>L. bulgaricus</i>	2
<i>L. casei</i>	9
<i>L. coryniformis</i>	2
<i>L. fermentum</i>	1
<i>L. gasseri</i>	4
<i>L. helveticus</i>	4
<i>L. jonsonii</i>	5
<i>L. paracasei</i>	5
<i>L. plantarum</i>	3
<i>L. reuteri</i>	3
<i>L. rhamnosus</i>	8
<b>Total</b>	<b>61</b>

Bifidobacteria	Number
<i>B. adolescentis</i>	2
<i>B. animalis</i>	18
<i>B. bifidum</i>	5
<i>B. breve</i>	3
<i>B. infantis</i>	2
<i>B. longum</i>	4
<b>Total</b>	<b>34</b>

### Potential effects

- Intestinal health
- Digestive health
- Natural defense
- Immune defense
- Skin health

Cited from;

<http://www.efosz.hu/letoltes/FCP28307E%20tudref1.pdf>

In addition to Lactobacilli, Bifidobacteria are also approved as major probiotic bacteria.

# Bifidobacteria are Applied as Food Additives and Dietary Supplements

Representative food supplemented with Bifidobacteria

↓  
**Yogurt**



Cited from; 'Morinaga Milk Industry Co., Ltd.' (<http://www.morinagamilk.co.jp/index.html>) and 'DANONE JAPAN Co., Ltd.' (<http://www.danone.co.jp/index.html>)


Bifidobacteria are ingested as dietary supplement




Cited from; 'MORISHITA JINTAN Co., Ltd.' (<http://www.jintan.co.jp/>) and 'SUNTORY LIMITED' (<http://www.suntory.co.jp/>)




## Alteration of Microbial Phase in Newborn Infant's Feces




## Alteration of Intestinal Microflora in Human Lifetime



# Metabolic Pathway of Sugar in Lactic Acid Bacteria




# Metabolic Pathway of Sugar in Bifidobacteria







# Analysis of Genomic DNA from *Bifidobacterium bifidum* JCM1254

Total number of contigues bp ; 2,218,867  
 Total number of presumed ORF ; 1,769




Clusters of Orthologous Groups (COG) classification	Ratio (%)
Amino acid transport and metabolism	9.3
Carbohydrate transport and metabolism	8.3
Cell cycle control, cell division, chromosome partitioning	2.1
Cell motility	0.5
Cell wall/membrane/envelope biogenesis	5.6
Chromatin structure and dynamics	0.1
Coenzyme transport and metabolism	3.4
Cytoskeleton	0.0
Defense mechanisms	3.3
Energy production and conversion	4.2
Extracellular structures	0.0
Function unknown	6.6
General function prediction only	10.9
Inorganic ion transport and metabolism	4.1
Intracellular trafficking, secretion, and vesicular transport	1.6
Lipid transport and metabolism	2.3
Not annotated	2.0
Nuclear structure	0.0
Nucleotide transport and metabolism	3.7
Posttranslational modification, protein turnover, chaperones	3.5
RNA processing and modification	0.1
Replication, recombination and repair	8.5
Secondary metabolites biosynthesis, transport and catabolism	1.0
Signal transduction mechanisms	3.3
Transcription	6.4
Translation, ribosomal structure and biogenesis	9.2



# Relationship between Intestinal Tract and Bifidobacteria




# Schematic Model of Sugar Chains on Cell Surface Membrane




# Structure of Determinant of ABO-type Blood Group Substances



**H(O)-type blood determinant**



**A-type blood determinant**




**B-type blood determinant**



# Distribution of 1,2- $\alpha$ -L-Fucosidase Activity in Bifidobacteria


culture fluid



Solvent;  $\text{CHCl}_3 : \text{CH}_3\text{OH} : \text{H}_2\text{O} = 3 : 3 : 1$


## Structure of 1,2- $\alpha$ -L-Fucosidase from *B.bifidum* JCM1254

**AfcA** (1959 amino acids) **Fuc  $\alpha$  1-2 Gal  $\beta$  1-3GlcNAc  $\beta$  1-3Gal  $\beta$  1-4Glc**




# Overall Structure of Catalytic Domain of 1,2- $\alpha$ -L-Fucosidase

alpha helical barrel domain



ribbon model

# Overall Structure of Catalytic Domain of 1,2- $\alpha$ -L-Fucosidase



ribbon model

molecular surface


electrostatic potential map

## Substrate Specificity of *B.bifidum* 1,2- $\alpha$ -L-Fucosidase


Substrate	Structure	Activity (%)	Substrate	Structure	Activity (%)
2'-FL	Gal $\beta$ 1 $\rightarrow$ 4Glc $\uparrow^2$ Fuc $\alpha$ 1	100	3-FL	Gal $\beta$ 1 $\rightarrow$ 4Glc $\uparrow^3$ Fuc $\alpha$ 1	trace
H(II)	Gal $\beta$ 1 $\rightarrow$ 4GlcNAc $\uparrow^2$ Fuc $\alpha$ 1	74	LNF P-V	Gal $\beta$ 1 $\rightarrow$ 3GlcNAc $\beta$ 1 $\rightarrow$ 3Gal $\beta$ 1 $\rightarrow$ 4Glc $\uparrow^3$ Fuc $\alpha$ 1	trace
H	Gal $\beta$ 1 $\uparrow^2$ Fuc $\alpha$ 1	27	LNF P-II	Gal $\beta$ 1 $\rightarrow$ 3GlcNAc $\beta$ 1 $\rightarrow$ 3Gal $\beta$ 1 $\rightarrow$ 4Glc $\uparrow^4$ Fuc $\alpha$ 1	ND
A	GalNAc $\alpha$ 1 $\rightarrow$ 3Gal $\beta$ 1 $\uparrow^2$ Fuc $\alpha$ 1	5.9	FDA C	GlcNAc $\beta$ 1 $\rightarrow$ 4GlcNAc Fuc $\alpha$ 1 $\downarrow^6$	ND
B	Gal $\alpha$ 1 $\rightarrow$ 3Gal $\beta$ 1 $\uparrow^2$ Fuc $\alpha$ 1	trace			
LNF P-I	Gal $\beta$ 1 $\rightarrow$ 3GlcNAc $\beta$ 1 $\rightarrow$ 3Gal $\beta$ 1 $\rightarrow$ 4Glc $\uparrow^2$ Fuc $\alpha$ 1	61	pNP- Fuc	Fuc $\alpha$ 1 $\rightarrow$ pNP Fuc $\beta$ 1 $\rightarrow$ pNP	ND

LNFP; lacto-*N*-fucopentaose    FDAC; fucosyldiacetylchitobiose    'Trace' indicates less than 1% activity.


# Schematic Model of Sugar Chains on Cell Surface Membrane



# Endo- $\alpha$ -N-acetylgalactosaminidase




# Endo- $\alpha$ -*N*-acetylgalactosaminidase Activity of Various Bifidobacteria








## Structure of Endo- $\alpha$ -N-acetylgalactosaminidase from *B.longum* JCM1217


**EngBF** (1966 Amino Acids) **Gal  $\beta$  1-3GalNAc  $\alpha$ -O-Thr/Ser**



# Crystal Structure of Endo- $\alpha$ -N-acetylgalactosaminidase




# Structure of Endo- $\alpha$ -N-acetylgalactosaminidase



## Substrate Specificity of *B.longum* Endo- $\alpha$ -*N*-acetylgalactosaminidase


Substrate	Type	Activity
GalNAc $\alpha$ - <i>p</i> NP	Tn antigen	—
Gal $\beta$ 1-3GalNAc $\alpha$ - <i>p</i> NP	Core 1 (T antigen)	+++
Gal $\beta$ 1-3(GlcNAc $\beta$ 1-6)GalNAc $\alpha$ - <i>p</i> NP	Core 2	—
GlcNAc $\beta$ 1-3GalNAc $\alpha$ - <i>p</i> NP	Core 3	+
GlcNAc $\beta$ 1-3(GlcNAc $\beta$ 1-6)GalNAc $\alpha$ - <i>p</i> NP	Core 4	—
GalNAc $\alpha$ 1-3GalNAc $\alpha$ - <i>p</i> NP	Core 5	—
GlcNAc $\beta$ 1-6GalNAc $\alpha$ - <i>p</i> NP	Core 6	—
GalNAc $\alpha$ 1-6GalNAc $\alpha$ - <i>p</i> NP	Core 7	—
Gal $\alpha$ 1-3GalNAc $\alpha$ - <i>p</i> NP	Core 8	—
Glc $\beta$ 1-3GalNAc $\alpha$ - <i>p</i> NP		++
Glc $\beta$ 1-6GalNAc $\alpha$ - <i>p</i> NP		—
GalNAc $\beta$ 1-3GalNAc $\alpha$ - <i>p</i> NP		++
Gal $\beta$ 1-6GlcNAc $\alpha$ - <i>p</i> NP		—
Gal $\alpha$ 1-6GalNAc $\alpha$ - <i>p</i> NP		—
Gal $\beta$ 1-3GlcNAc $\alpha$ - <i>p</i> NP		±
Gal $\beta$ 1-3GalNAc-SPh		±

# Putative Metabolic Pathway of Mucin Sugar Chain on *Bifidobacterium longum*




# Model Structure of Human Milk Oligosaccharides


## Disaccharide composition




## Modified sugar



## Similarity of Core Structure of Mucin Sugar Chain with Core Structure of Human Milk Oligosaccharides



**Core structure of sugar chain of Mucin glycoprotein**



**Core structure of human milk oligosaccharides**




Lacto-*N*-biose





## Structure of Lacto-*N*-biosidase from *B.bifidum* JCM1254

**LNBase** (1112 Amino Acids) **Gal  $\beta$  1-3GlcNAc  $\beta$  1-3Gal  $\beta$  1-4Glc**




# Schematic Diagram of Structures of Two Sialidases

## Esterase Activity of SiaBb1-Expressed Cell


SiaBb1


1795 AA

chlor




SiaBb1





# Crystal Structure of Solute Binding Protein of ABC-Transporter from *B.longum* Specific for Lacto-*N*-biose




Solute binding protein of ABC transporter for sugars  
1317 bp, 438 amino acids

# Functional Analysis of Solute Binding Protein


## Isothermal titration calorimetry analysis

**Gal ( $\beta$  1-3) GalNAc**




Protein; 5  $\mu$ M  
Ligand; 100  $\mu$ M

**Gal ( $\beta$  1-3) GlcNAc**




Protein; 10  $\mu$ M  
Ligand; 200  $\mu$ M

**Gal ( $\beta$  1-4) GlcNAc**



Protein; 10  $\mu$ M  
Ligand; 200  $\mu$ M



**Galactose  $\beta$ 1-3 N-Acetylaminosugar**

## Effect of Addition of Various Sugars on Growth of Bifidobacteria

Sugar	Structure	Relative growth
None		35
<i>Non-prebiotic sugars</i>		
Glucose	Glc	100
Lactose	Gal- $\beta$ 1,4-Glc	101
<i>Prebiotic oligosaccharides</i>		
Fructo-oligosaccharides	Glc- $\beta$ 1,2-Fru(- $\beta$ 2,1-Fru) <sub>n</sub>	68
Isomalto-oligosaccharides	Glc(- $\alpha$ 1,6-Glc) <sub>n</sub> Glc- $\alpha$ 1,6-Glc- $\alpha$ 1,4-Glc	84
Gentio-oligosaccharides	Glc(- $\beta$ 1,6-Glc) <sub>n</sub>	73
Xylo-oligosaccharides	Xyl(- $\beta$ 1,4-Xyl) <sub>n</sub>	36
Raffinose	Gal- $\alpha$ 1,6-Glc- $\beta$ 1,2-Fru	99
<b>Lacto-N -biose</b>	<b>Gal-<math>\beta</math>1,3-GlcNAc</b>	<b>85</b>

## Effect of Addition of Lacto-*N*-biose to Culture Medium on Growth of Various Bifidobacteria

Bacteria (strain)	Growth (LNB / None)	
	24 h	48 h
<b>Bifidobacteria</b>		
<i>B.adolescentis</i> (JCM1275)	+	+
<i>B.angulatum</i> (JCM7096)	-	-
<i>B.animalis lactis</i> (JCM10602)	±	±
<i>B.bifidum</i> (JCM1254)	+	++
<i>B.bifidum</i> (JCM1255)	-	±
<i>B.bifidum</i> (JCM7004)	+	+
<i>B.breve</i> (JCM1192)	+	+
<i>B.catenulatum</i> (JCM1194)	+	+
<i>B.gallicum</i> (JCM8224)	±	±
<i>B.longum</i> (JCM1217)	++	++
<i>B.longum</i> (JCM1222)	+	++
<i>B.longum</i> (JCM7054)	++	++
<i>B.pseudocatenulatum</i> (JCM1200)	+	+
<i>B.pseudolongum pseudolongum</i> (JCM1205)	±	±
<i>B.scardovii</i> (JCM12489)	-	±

++	→ Highly effective	(LNB/None = 2.00 ~ 2.99)
+	→ Effective	(LNB/None = 1.20 ~ 1.99)
±	→ No effect	(LNB/None = 0.80 ~ 1.19)
-	→ Inhibit	(LNB/None = ~ 0.79)



## Effect of Addition of Lacto-*N*-biose to Culture Medium on Growth of Various Intestinal Microorganisms

Bacteria (strain)	Growth (LNB / None)	
	24 h	48 h
<b>Bacteroides</b>		
<i>B.ovatus</i> (JCM5824)	+	+
<i>B.thetaiotaomicron</i> (JCM5827)	+	±
<b>Clostridia</b>		
<i>C.celatum</i> (JCM1394)		
<i>C.hiranonis</i> (JCM10541)	±	±
<i>C.hylemonae</i> (JCM10539)	+	+
<i>C.spiroforme</i> (JCM1432)		
<i>C.scindens</i> (JCM6567)	-	+
<b>Enterococci</b>		
<i>E.pseudoavium</i> (JCM8732)	±	±
<i>E.raffinosis</i> (JCM8733)	±	+
<b>Eubacteria</b>		
<i>E.limosum</i> (JCM6421)	±	±
<i>E.cylindroides</i> (JCM10261)		
<b>Propionibacteria</b>		
<i>P.acnes</i> (JCM6425)	±	+
++	→ Highly effective	(LNB/None = 2.00 ~ 2.99)
+	→ Effective	(LNB/None = 1.20 ~ 1.99)
±	→ No effect	(LNB/None = 0.80 ~ 1.19)
-	→ Inhibit	(LNB/None = ~ 0.79)

# Acknowledgement

Kyoto University,  
Graduate School of Biostudies

Dr.Y.Makimura  
Ms.N.Nagamine  
Ms.A.Sakuma  
Ms.A.Tsuchiya

Shizuoka University,  
Faculty of Agriculture  
Prof.T.Usui  
Dr.T.Murata

High Energy Accelerator Research  
Organization (KEK)


Dr.S.Wakatsuki  
Dr.R.Katoh  
Dr.M.Nagae

Ishikawa Prefectural University

Prof.H.Kumagai  
Mr.J.Wada

The University of Tokyo,  
Department of Biotechnology


R.Suzuki  
S.Fushinobu



Thank you for your attentions !

謝謝！

## Candidate for Catalytic Residues of 1,2- $\alpha$ -L-Fucosidase



## Binding Activity of *Lactobacillus casei* to Various Glycosphingolipids

Glycolipids	Structure	Relative Binding activity
Glucosylceramide	Glc $\beta$ 1-1'Cer	72
Galactosylceramide	Gal $\beta$ 1-1'Cer	46
Lactosylceramide	Gal $\beta$ 1-4Glc $\beta$ 1-1'Cer	89
CTH	Gal $\alpha$ 1-4Gal $\beta$ 1-4Glc $\beta$ 1-1'Cer	100
Globoside	GalNAc $\beta$ 1-3Gal $\alpha$ 1-4Gal $\beta$ 1-4Glc $\beta$ 1-1'Cer	0
Forssman hapten	GalNAc $\alpha$ 1-3GalNAc $\beta$ 1-3Gal $\alpha$ 1-4Gal $\beta$ 1-4Glc $\beta$ 1-1'Cer	0
GM3	NeuAc $\alpha$ 2-3Gal $\beta$ 1-4Glc $\beta$ 1-1'Cer	0
GM2	GalNAc $\beta$ 1-4(NeuAc $\alpha$ 2-3)Gal $\beta$ 1-4Glc $\beta$ 1-1'Cer	0
GM1	Gal $\beta$ 1-3GalNAc $\beta$ 1-4(NeuAc $\alpha$ 2-3)Gal $\beta$ 1-4Glc $\beta$ 1-1'Cer	0
GD3	NeuAc $\alpha$ 2-8NeuAc $\alpha$ 2-3Gal $\beta$ 1-4Glc $\beta$ 1-1'Cer	0
GD1a	NeuAc $\alpha$ 2-3Gal $\beta$ 1-3GalNAc $\beta$ 1-4(NeuAc $\alpha$ 2-3)Gal $\beta$ 1-4Glc $\beta$ 1-1'Cer	0
GT1b	NeuAc $\alpha$ 2-3Gal $\beta$ 1-3GalNAc $\beta$ 1-4Gal $\beta$ 1-4Glc $\beta$ 1-1'Cer	0
	3	
	NeuAc $\alpha$ 2-8NeuAc $\alpha$ 2	
GQ1b	NeuAc $\alpha$ 2-8NeuAc $\alpha$ 2-3Gal $\beta$ 1-3GalNAc $\beta$ 1-4Gal $\beta$ 1-4Glc $\beta$ 1-1'Cer	0
	3	
	NeuAc $\alpha$ 2-8NeuAc $\alpha$ 2	
GA1	Gal $\beta$ 1-3GalNAc $\beta$ 1-4Gal $\beta$ 1-4Glc $\beta$ 1-1'Cer	94
Lc4	Gal $\beta$ 1-4GlcNAc $\beta$ 1-3Gal $\beta$ 1-4Glc $\beta$ 1-1'Cer	35
SPG	NeuAc $\alpha$ 2-3Gal $\beta$ 1-4GlcNAc $\beta$ 1-3Gal $\beta$ 1-4Glc $\beta$ 1-1'Cer	0
Sulfatide	HSO <sub>3</sub> -3Gal $\beta$ 1-1'Cer	27

Gal, D-galactose; GalNAc, N-acetylgalactosamine; Glc, D-glucose; GlcNAc, N-acetylglucosamine; NeuAc, N-acetylneuraminic acid; Cer, ceramide

## Binding Activities of *Lactobacillus* to Various Glycosphingolipids

Glycosphingolipids	Structure	<i>Lb.casei</i>	<i>Lb.reuteri</i>	<i>Lb.johnsonii</i>
Glucosylceramide	Glcβ1-1'Cer	++	-	+
Galactosylceramide	Galβ1-1'Cer	+	+	nd
Lactosylceramide	Galβ1-4Glcβ1-1'Cer	++	+	nd
CTH	Galα1-4Galβ1-4Glcβ1-1'Cer	++	-	-
Isotriaose	Galα1-3Galβ1-4Glcβ1-1'Cer	nd	nd	+
Globoside	GalNAcβ1-3Gal α1-4Galβ1-4Glcβ1-1'Cer	-	-	-
Forssman hapten	GalNAcα1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ1-1'Cer	-	-	-
GM3	NeuAcα2-3Galβ1-4Glcβ1-1'Cer	-	-	-
GM2	GalNAcβ1-4(NeuAcα2-3)Galβ1-4Glcβ1-1'Cer	-	-	nd
GM1	Galβ1-3GalNAcβ1-4(NeuAcα2-3)Galβ1-4Glcβ1-1'Cer	-	-	nd
GD3	NeuAcα2-8NeuAcα2-3Galβ1-4Glcβ1-1'Cer	-	nd	nd
GD1a	NeuAcα2-3Galβ1-3GalNAcβ1-4(NeuAcα2-3)Galβ1-4Glcβ1-1'Cer	-	-	nd
GT1b	NeuAcα2-3Galβ1-3GalNAcβ1-4Galβ1-4Glcβ1-1'Cer	-	nd	nd
	3			
	NeuAcα2-8NeuAcα2			
GQ1b	NeuAcα2-8NeuAcα2-3Galβ1-3GalNAcβ1-4Galβ1-4Glcβ1-1'Cer	-	nd	nd
	3			
	NeuAcα2-8NeuAcα2			
<b>GA1</b>	<b>Galβ1-3GalNAcβ1-4Galβ1-4Glcβ1-1'Cer</b>	<b>++</b>	<b>++</b>	<b>++</b>
Lc4	Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ1-1'Cer	+	nd	+
Lactotetraose	Galβ1-3GlcNAcβ1-3Galβ1-4Glcβ1-1'Cer	nd	nd	+
SPG	NeuAc α2-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ1-1'Cer	-	nd	-
Sulfatide	HSO <sub>3</sub> -3Galβ1-1'Cer	+	+	-

Gal, D-galactose; GalNAc, *N*-acetylgalactosamine; Glc, D-glucose; GlcNAc, *N*-acetylglucosamine; NeuAc, *N*-acetylneuraminic acid; Cer, ceramide. nd : not done.

## 乳酸菌による抗体産生増強作用

